JPWO2020247843A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247843A5 JPWO2020247843A5 JP2021572298A JP2021572298A JPWO2020247843A5 JP WO2020247843 A5 JPWO2020247843 A5 JP WO2020247843A5 JP 2021572298 A JP2021572298 A JP 2021572298A JP 2021572298 A JP2021572298 A JP 2021572298A JP WO2020247843 A5 JPWO2020247843 A5 JP WO2020247843A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- polypeptide
- amino acid
- seq
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025000023A JP2025060983A (ja) | 2019-06-05 | 2025-01-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857726P | 2019-06-05 | 2019-06-05 | |
| US62/857,726 | 2019-06-05 | ||
| PCT/US2020/036454 WO2020247843A2 (en) | 2019-06-05 | 2020-06-05 | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025000023A Division JP2025060983A (ja) | 2019-06-05 | 2025-01-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022535130A JP2022535130A (ja) | 2022-08-04 |
| JP2022535130A5 JP2022535130A5 (https=) | 2023-06-13 |
| JPWO2020247843A5 true JPWO2020247843A5 (https=) | 2023-06-13 |
| JP7778571B2 JP7778571B2 (ja) | 2025-12-02 |
Family
ID=73652315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572298A Active JP7778571B2 (ja) | 2019-06-05 | 2020-06-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
| JP2025000023A Pending JP2025060983A (ja) | 2019-06-05 | 2025-01-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025000023A Pending JP2025060983A (ja) | 2019-06-05 | 2025-01-05 | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220251202A1 (https=) |
| EP (1) | EP3980051A4 (https=) |
| JP (2) | JP7778571B2 (https=) |
| KR (1) | KR20220083660A (https=) |
| CN (1) | CN114786708A (https=) |
| AU (1) | AU2020287373B2 (https=) |
| CA (1) | CA3142738A1 (https=) |
| WO (1) | WO2020247843A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| US20210017247A1 (en) | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| WO2020057646A1 (zh) | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| CN114728040A (zh) * | 2019-06-14 | 2022-07-08 | 科优基因公司 | 新型白介素-2变体及其双功能融合分子 |
| WO2021142471A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| TW202216745A (zh) * | 2020-07-02 | 2022-05-01 | 美商英伊布里克斯公司 | 包含經修飾ｉｌ－２多肽之多肽及其用途 |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| AU2022253351A1 (en) * | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| US20240199714A1 (en) * | 2021-04-16 | 2024-06-20 | Orionis Biosciences, Inc. | Il-2 based constructs |
| AU2022275666A1 (en) | 2021-05-19 | 2023-12-07 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| US20250002601A1 (en) | 2021-06-09 | 2025-01-02 | Innate Pharma | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
| WO2023004304A1 (en) * | 2021-07-20 | 2023-01-26 | Inhibrx, Inc. | Cd8-binding polypeptides and uses thereof |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| CA3227386A1 (en) * | 2021-07-28 | 2023-02-02 | Jianing Huang | Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications |
| CA3238260A1 (en) * | 2021-11-17 | 2023-05-25 | John Thomas MULLIGAN | Compositions of protein complexes and methods of use thereof |
| CN116554344A (zh) * | 2022-01-30 | 2023-08-08 | 中国科学院生物物理研究所 | 一种pd1抗体与白介素2融合的双功能分子 |
| CA3259108A1 (en) * | 2022-06-16 | 2023-12-21 | Cephalon Llc | Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses |
| EP4556493A1 (en) * | 2022-07-11 | 2025-05-21 | Genuv Inc. | Cytokine fusion protein |
| EP4605422A2 (en) * | 2022-10-20 | 2025-08-27 | Repertoire Immune Medicines, Inc. | Cd8 t cell targeted il2 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
| CN118680877A (zh) * | 2023-03-21 | 2024-09-24 | 信达生物制药(苏州)有限公司 | 抗pd-1与突变il-2免疫缀合物制剂 |
| US20250195677A1 (en) * | 2023-12-19 | 2025-06-19 | Cephalon Llc | Uses for attenuated il-2 immunoconjugates |
| TW202545980A (zh) * | 2024-02-01 | 2025-12-01 | 瑞典商阿斯特捷利康公司 | Ｃｄ８結合細胞介素銜接器及其使用方法 |
| CN118373896B (zh) * | 2024-04-19 | 2025-07-29 | 上海科棋药业科技有限公司 | 抗pd-1抗体与il-2突变体的双功能融合蛋白 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| ES2534085T3 (es) * | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| KR102042246B1 (ko) | 2014-02-06 | 2019-11-28 | 에프. 호프만-라 로슈 아게 | 인터류킨-2 융합 단백질 및 이의 용도 |
| WO2017027422A1 (en) * | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| RU2761377C2 (ru) * | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| KR20190136076A (ko) * | 2017-04-13 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제 |
| JP2020521452A (ja) * | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| US20200299349A1 (en) | 2017-11-21 | 2020-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
| EP4232071A4 (en) * | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
-
2020
- 2020-06-05 AU AU2020287373A patent/AU2020287373B2/en active Active
- 2020-06-05 WO PCT/US2020/036454 patent/WO2020247843A2/en not_active Ceased
- 2020-06-05 CA CA3142738A patent/CA3142738A1/en active Pending
- 2020-06-05 KR KR1020227000163A patent/KR20220083660A/ko active Pending
- 2020-06-05 JP JP2021572298A patent/JP7778571B2/ja active Active
- 2020-06-05 CN CN202080051337.9A patent/CN114786708A/zh active Pending
- 2020-06-05 EP EP20819187.4A patent/EP3980051A4/en active Pending
- 2020-06-05 US US17/616,157 patent/US20220251202A1/en active Pending
-
2025
- 2025-01-05 JP JP2025000023A patent/JP2025060983A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020247843A5 (https=) | ||
| JP7778571B2 (ja) | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 | |
| JP6464255B2 (ja) | 二重特異性ｔ細胞活性化抗原結合分子 | |
| CN111527109A (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| CA3199447A1 (en) | Fusions with cd8 antigen binding molecules for modulating immune cell function | |
| RS56879B1 (sr) | Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija | |
| RS55229B1 (sr) | Heterodimerni vezujući proteini i njihove upotrebe | |
| CA3205670A1 (en) | Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 | |
| CA3147677A1 (en) | Engineered interleukin-2 receptor beta agonists | |
| JP2024508949A (ja) | Ｐｄ－１標的化ｉｌ－２変異体イムノコンジュゲートとｆａｐ／４－１ｂｂ結合分子との併用療法 | |
| TW202237630A (zh) | 用於調節免疫細胞功能之突變介白素－１０多肽與抗原結合分子之融合體 | |
| US20250339519A1 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| US20260098090A1 (en) | Fusions with cd8 antigen binding molecules for treating chronic viral infection | |
| JP2025521087A (ja) | 改変インターロイキン２受容体ベータ結合減少アゴニスト | |
| CA3220027A1 (en) | Bispecific fc fusion proteins with spd-1 and il-15 | |
| Li et al. | Advancing immunotherapy via multiple immune cells co-engagement | |
| WO2025233431A1 (en) | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |